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1. Introduction 
Flagyl [1] is the trade name ofmetronidazole, 
1-(2-hydroxyethyl)- 2-methyl-5-nitroimidaz ole,the 
drug most commonly employed in the treatment of 
infections of the vagina by Trichomonas vaginalis. 
Recently it has been widely used against entamoebal 
infections. Flagyl has also been demonstrated to pro- 
duce aversion to ethanol, and was suggested as a repres- 
sent of  compulsive consumption of alcohol [2]. 
The ability of mammalian icotinamide adenine 
dinucleotide nucleosidases (EC 3.2.2.5) to catalyse 
transglycosylation reactions is well established, and 
has been elegantly exploited for the synthesis of a 
multitude of analogues, largely in the laboratories of 
Kaplan, working with pyridine derivatives [3 -13] ,  
and Alivisatos, working with imidazole derivatives 
[14-25] .  
Analogue formation has been implicated in the 
action of  drugs [26-32]  and in synthetic pathways 
[ 14,18,25,33]. Imidazolysis may be involved in the 
mechanism of anaphylactic shock [15,19,21,34,35] 
and also the mechanism of  action of  NAD nucleosi- 
dase itself [24]. 
We report in this communication new analogues, 
in which the nicotinamide moiety of NAD and 
NADP is replaced by Flagyl. These we will refer to 
as FlagAD and FlagADP respectively. 
* Present address: Biological Laboratory, University of Kent, 
Canterbury, Kent, England. 
2. Materials and methods 
The method of synthesis and purification of  
FlagAD and FlagADP, the analogue of NADP, is 
shown in Fig. 1. The conditions for the actual trans- 
glycosylation reaction are based on those of Kaplan 
[ 11 ], whereas the column chromatographic separation 
of the analogue from the other reaction products is 
an adaptation of  the method of Chaykin et al. [36], 
which utilises the volatile ammonium bicarbonate 
both to maintain the appropriate pH and to provide 
10. 
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12. 
Fig. 
1. Dissolve 1000 mg Flagyl in 50 ml phosphate buffer 
(0.05 I, pH 7.2) using heat. 
2. Cool to 37°C, add 50 mg NAD and 125 mg calf spleen 
NADase and incubate at 37°C for 3 hr. 
3. Centrifuge at 27 000g for 10 min at 4°C discard 
pellet. 
4. Add supernatant to an ion-exchange column, DE 52, 
20 cm × 2.1 cm, 30 ml/hr, equilibrated with 0.005 M 
ammonium bicarbonate. 
5. Elute with a linear gradient of ammonium bicarbonate 
from 0.005 M to 0.5 M, monitoring effluent at 260 nm. 
6. Bulk fractions of each peak and freeze dry. 
7. Measure the UV spectrum of th~ material from each 
peak. 
8. Store the 'FlagAD', the mixed product including FlagAD, 
at -15°C. 
9. Run 20 mg of this product in a TLC system consisting 
of a 0.75 mm layer of MN300 with a solvent system of 
tertiary amyl alcohol, formate and water (3:2:1). 
Identify spots with UV light, elute in water, and freeze- 
dry products. 
Measure the UV spectrum of each product. 
Store the FlagAD at - 15°C. 
1. Methodology of the synthesis of FlagAD. 
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the elution gradient. The thin layer chromatographic 
method employed cellulose powder MN300, with a 
solvent system consisting of tertiary amyl alcohol, 
formic acid and water in the ratio 3:2:1. The spots 
were located with ultraviolet light. To scale up this 
method, grooved plates (May and Baker Ltd ) were 
used with a thicker (0.75 mm) cellulose layer. 
Spectrophotometric measurements were made 
on a Cary 14 spectrophotometer. Flagyl was obtained 
from May and Baker Ltd., Dagenham, Essex, England. 
DE52 column chromedia was obtained from What- 
man, MN300 cellulose powder was supplied by Cam- 
lab, Cambridge, England. Calf spleen NADase was 
obtained from Boehringer Co. (London) Ltd. 
3. Results 
Typical profiles of the ion exchange column efflu- 
ents are shown in fig. 2. A better separation of peaks 
is obtained in the FlagADP experiment, due to the 
extra negative charge of the product. Freeze-drying 
of the bulked fractions corresponding to each peak 
removed most of the contaminating ammonium 
bicarbonate, leaving white residues. The absorbance 
spectrum of the analogue-containing peak, in each 
experiment, showed a maximum at 320 nm as well 
as the usual 260 nm nucleotide absorption. This 
contrasts with the spectra of Flagyl itself, NAD, and 
a theoretical spectrum of FlagAD, calculated assu- 
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Fig. 2. Chromatographic purification of 'FlagAD' and 'FlagADP' on DEAE cellulose, and the spectra of the analogue-containing 
peaks. A, 'FlagADP'; B, 'FlagAD'. 
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Fig. 3. Spectrum of'FlagAD', as eluted from the DEAE cel- 
lulose column, compared with the spectra of the components 
and the theoretical spectrum of the analogue. A, 114 ,M 
Flagyl; B, 62.6 pM ADPR; C, theoretical 50 pM FlagAD; D, 
peak, containing FlagAD, eluted from the DE52 column. 
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Fig. 5. Spectrum of FlagAD. 
ming that both components contribute their 'free' 
spectrum to the new nucleotide (fig. 3). 
This material ('FlagAD') of the analogue-con- 
taining peak when run in the TLC system was found 
to split into two major and two minor spots (fig. 4). 
None of these corresponded to Flagyl or NAD, but 
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Fig. 4. Purification of FlagAD by Thin Layer Chromatograp- 
hy. Spots: A, ADPR; B, Flagyl; C. peak 1 from DE52; D, peak 
containing FlagAD from DE52; E, NAD; F, ADP. 
one of the major spots, 1, ran with the marker 
ADPR, and one of the minor spots, 3, ran as ADP. 
Spot 2 corresponded to none of the added marker 
nucleotides. The compound eluted from this spot 
was found to possess aspectrum (fig. 5) very simi- 
lar to the calculated, theoretical spectrum of FlagAD. 
We concluded that this was our pure analogue. 
Imidazolysis i reported to be irreversible [22,24, 
25]. However this new nucleotide was found to be 
slowly hydrolysed to release Flagyl (as identified by 
its absorbance and acid difference spectra), in a reac- 
tion catalysed by NAD nucleosidase (fig. 6). The 
reaction in the hydrolytic direction is very slow com- 
pared with the synthesis. 
4. Discussion 
The demonstration that Flagyl will exchange with 
the nocotinamide moiety of NAD or NADP to pro- 
duce new nucleotides raised the question as to whe- 
ther this process may be an integral part of the toxity 
of Flagyl to various anaerobic organisms. This possi- 
bility has been fully tested and the results of these 
experiments [37] do not suggest that the analogue 
is involved. 
Flagyl is known to have anti-alcohol activity, 
and the main research into the mode of this action has 
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Fig. 6. Hydrolysis of FlagAD. Incubation mixture contained 
20 mg 'FlagAD', as eluted from the DE52 column, 45 mg calf 
spleen NADase, and 1.5 ml phosphate buffer (0.05 I, pH 7.2), 
and was at 37 ° C. The reaction was stopped by the addition 
of 0.1 ml 5M TCA, and the mixture was then centrifuged. 
The supernatant was neutralised with 1 M NaOH, and 0.75 
ml of it applied to a G-10 sephadex column, 30 cm by 2.1 
cm, flowing at 30 ml hour, and eluted with phosphate buffer 
(0.05 I, pH 7.2). Length of incubation: A, 48 hr, control, no 
enzyme; B, 19.5 hr; C, 6.3 hr. 1, absorbance at260 nm; 2, ab- 
sorbance at 320 nm. 
involved the study of the inhibition by Flagyl of vari- 
ous of the enzymes involved in the oxidation of etha- 
nol [38-42] .  The validity of some of this work has 
been questioned [43], and in some cases it is likely 
that the apparent inhibitions are simply due to spec- 
trophotometric artefacts. It has recently been shown 
[44] that a reported chemical reaction between 
Flagyl and NADH [43] was just this. As yet no satis- 
factory mechanism has been proposed for the anta- 
gonism between Flagyl and ethanol although FlagAD 
or FlagADP might well be involved. 
This is the first time to our knowledge that an 
imidazolytic reaction has been demonstrated to be 
reversible. This reversibility can possibly be explained 
by the possession of a substituent, in Flagyl, on the 
second nitrogen of the imidazole ring. As a conse- 
quence of this substitution the positive charge pro- 
duced on the combination of Flagyl with the ADPR 
moiety cannot be lost by ionisation of a proton as 
with analogues containing non-substituted imidazoles. 
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